- Home
- SOC vs INVA Comparison
SOC vs INVA Comparison
Compare SOC & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$20.98
Company Overview
Basic Information| Metric | SOC | INVA |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SOC | INVA |
|---|---|---|
| Price | $4.31 | $20.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $17.33 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 6.5M | 575.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 816.67 |
| EPS | N/A | ★ 1.25 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | $73.55 | $12.65 |
| P/E Ratio | ★ N/A | $16.83 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $2.88 | $16.52 |
| 52 Week High | $24.64 | $25.15 |
Technical Indicators
Market Signals| Indicator | SOC | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 53.35 |
| Support Level | $3.94 | $20.44 |
| Resistance Level | $4.61 | $21.81 |
| Average True Range (ATR) | 0.33 | 0.42 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 16.09 | 76.89 |
Price Performance
Historical Comparison SOC
INVA
About SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.